Kornimate/medical-research-clean huggingface dataset:
effects of reduction in saturated fat on cholesterol and lipoproteins in lean and obese persons

Conditions: Cardiovascular Disease; Dietary Modification; Cardiovascular Risk Factors

Summary: a randomized controlled clinical trial comparing the effect of substitution of unsaturated fat from nuts and oils for saturated fat from meat and dairy foods on serum lipids in normal weight and obese subjects with elevated ldl cholesterol.

background: increased intake of saturated fat may influence ldl cholesterol and other cardiovascular risk factors different in normal weight and obese subjects. methods: the study is a randomized controlled clinical trial in 84 men and women between 21 to 70 years with normal bmi (25 kg/m2) or obesity (bmi 30-45 kg/m2) and elevated ldl cholesterol (\>3.0 mmol/l). dietary intervention: randomization will be to one of two balanced weight maintenance mediterranean-type diets that differ in their fat sources: an intervention diet substituting unsaturated fats from oil and nuts for saturated fats from meat and dairy foods, and a control diet with whole fat dairy and meat with saturated fats that are not fat reduced. primary research question: compare the effect of substitution of unsaturated fat from nuts and oils for saturated fat from meat and dairy foods on serum lipids in normal weight and obese subjects with elevated ldl cholesterol. secondary research questions: compare the effect of substitution of unsaturated fat from nuts and oils for saturated fat on cardiometabolic risk factors including insulin resistance, inflammation and serum pcsk9 in normal weight and obese individuals.

Eligibility criteria:
inclusion criteria: * men and women aged 21 to 70 years with normal bmi (25 kg/m2) or obesity (bmi 30-45 kg/m2) and elevated ldl cholesterol (\> 3.0 mmol/l). exclusion criteria: * diabetes types 1 and 2 * history of cvd including myocardial infarction, percutaneous coronary intervention (pci), coronary artery bypass grafting (cabg), stroke, transient ischemic attack (tia) or other atherosclerotic disease, eating disorder and other secondary causes of hyperlipidemia. * use of statins or other cholesterol-modifying drugs. * genetic lipid disorder. * gastrointestinal disorders that limit food choices. * psychiatric illness, drug or alcohol abuse.
the application of a novel urinalysis system (uf-5000) for reducing unnecessary antibiotic use in clinical suspected uti patients

Conditions: Urinary Tract Infections; Urinary Tract Infection Lower Acute

Summary: urinary tract infection (uti) is one of the most common diseases in population while antibiotic resistant in uti has become a critical problem in hong kong, that a large proportion of the bacteria in uti resistant to commonly used anti-uti antibiotic treatment. this is largely due to the empirical treatment (i.e. no bacteria information is available at the time of treatment) and overtreatment of antibiotics in the past decades. some patients who did not actually have uti were prescribed with antibiotics because they have symptoms similar to uti. in order to avoid unnecessary use of antibiotics and therefore reduce the antibiotic resistance rates of uti, we propose to apply a new urine sediment analyzer (uf-5000) in clinical practice for uti which could provide quick label for potential bacteria in urine, and give more information on the possible species of the bacteria. uf-5000 is a urine sediment analyzer manufactured by sysmex ltd. (japan), it is widely used in central laboratories of hospitals and private laboratories, but not commonly seen in out-patient clinic setting. uf-5000 is capable of counting the amount of bacteria present in the given urine sample and provide gram staining\*, with results available within 5 minutes. while routine urine culture would take around 3 days. a study done by the university of hong kong in 2019 has shown that uf-5000 has higher accuracy than conventional dipstick, with reliable gram staining result. it has a negative-prediction value of 96%, which means it could accurately identify the cases who had no uti but only similar symptoms. those cases were mostly inflammatory diseases that did not require antibiotics. this study aims to evaluate whether bacteria information provided by uf-5000 would be able to guide a precision use of antibiotic treatment and avoid unnecessary antibiotic use.


Eligibility criteria:
inclusion criteria: 1. adult patients who are suspected to have luts in outpatient clinic. 2. willing to consent to participate the trial. 3. be able to understand the nature of the study. exclusion criteria: 1. any suspected or known sexual transmitted diseases. (such as gonorrhea, etc.) 2. use of any systematic antibiotics or antiviral treatment within two weeks 3. with evidence of systematic infection including high fever, significantly increase of blood white blood cell count, etc. 4. known or suspected allergic history/adverse drug reactions to any antibiotics 5. with previous history of multidrug resistant (mdr) bacterial infection. 6. any medical history that indicates the need of immediate antibiotics treatment, such as chronic conditions and/or taking immunosuppressants.
triprilimab(js001) and chemotherapy combined with local treatment for multiple metastatic npc

Conditions: Nasopharyngeal Carcinoma

Summary: this study is a randomized, phase ii, prospective, multicenter clinical trial to evaluate the efficacy and tolerability of js001 and chemotherapy combined with local treatment in patients with multiple metastatic nasopharyngeal carcinoma.


Eligibility criteria:
inclusion criteria: 1. patients with multiple metastases at first diagnosis or multiple metastases after treatment(multiple metastases was defined as more than 5 lesions and/or more than 2 metastasis organs); histologically or cytologically confirmed multiple metastatic npc. 2. eastern cooperative oncology group (ecog) performance status of 0 to 2 at trial entry, and life expectancy ≥6months as judged by the investigator; 3. the disease must be measurable with at least 1 unidimensional measurable lesion by response evaluation criteria in solid tumors (recist) version 1.1; 4. adequate organ function; 5. take adequate contraceptive measures throughout the study, and contraception continues until 12 months after treatment; 6. able and willing to provide signed informed consent form, and able to comply with all procedures. 7. the time from the last chemotherapy and/or radiotherapy to randomization must be ≥6 months. exclusion criteria: 1. patients with a hypersensitivity to any of the drugs used in our study; 2. with any active autoimmune disease or history of autoimmune disease; 3. clinically significant cardiovascular and cerebrovascular diseases; 4. have or are suffering from other malignant tumors within 5 years (except non-melanoma skin cancer or pre-invasive cervical cancer); 5. active systemic infection; 6. drug or alcohol abuse; 7. no or limited capacity for civil conduct; 8. the patient has a physical or mental disorder, and the researcher considers that the patient is unable to fully or fully understand the possible complications of this study; 9. history of immunodeficiency including seropositive for human immunodeficiency virus (hiv), or other acquired or congenital immune-deficient disease, or any active systemic viral infection requiring therapy； 10. use cortisol or other systematic immunosuppressive medications within 4 weeks before the study treatment, and subject requiring hormone therapy during trials. 11. pregnancy or breast feeding.
location specific differences in intestinal brake activation

Conditions: Ileal Brake; Satiety; Overweight; Obesity; Overeating

Summary: the appearance of intact macronutrients in the small intestine can result in the activation of an intestinal brake; a negative feedback mechanism from different parts of the intestine to the stomach, the small intestine and to the central nervous system. these processes inhibit food processing, appetite sensations and food intake, and furthermore they increase feelings of satiety and satiation. the researchers will investigate the effects of intraduodenal, intrajejunal and intralileal infusion of casein (protein) on ad libitum food intake, satiation and in vivo release of the gut satiety peptides cck, pyy and glp-1 and glucose and insulin.


Eligibility criteria:
inclusion criteria in order to be eligible to participate in this study, a subject must meet all of the following criteria: * based on medical history and previous examination, no gastrointestinal complaints can be defined. * age between 18 and 65 years. this study will include healthy adult subjects (male and female). women must be taking contraceptives. * bmi between 18 and 25 kg/m2) * weight stable over at least the last 6 months (≤5% weight change) exclusion criteria a potential subject who meets any of the following criteria will be excluded from participation in this study: * history of severe cardiovascular, respiratory, urogenital, gastrointestinal/ hepatic, hematological/immunologic, heent (head, ears, eyes, nose, throat), dermatological/connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurological/psychiatric diseases, allergy, major surgery and/or laboratory assessments which might limit participation in or completion of the study protocol. the severity of the disease (major interference with the execution of the experiment or potential influence on the study outcomes) will be decided by the principal investigator. * use of medication, including vitamin supplementation, except oral contraceptives, within 14 days prior to testing * administration of investigational drugs or participation in any scientific intervention study which may interfere with this study (to be decided by the principle investigator), in the 180 days prior to the study * major abdominal surgery interfering with gastrointestinal function (uncomplicated appendectomy, cholecystectomy and hysterectomy allowed, and other surgery upon judgement of the principle investigator) * dieting (medically prescribed, vegetarian, diabetic, macrobiological, biological dynamic) * pregnancy, lactation * excessive alcohol consumption (\>20 alcoholic consumptions per week) * smoking * blood donation within 3 months before the study period * self-admitted hiv-positive state * weight \<60kg * evidence of casein or sucrose hypersensitivity * participation in any other study in which radiation was used, within 12 months before the study period
efficacy of tak-438 compared to placebo in the treatment of non-erosive gastroesophageal reflux disease

Conditions: Non-erosive Gastroesophageal Reflux Disease

Summary: the purpose of this study is to investigate the superiority of efficacy of tak-438, once daily (qd), to placebo in patients with non-erosive gastroesophageal reflux disease.


Eligibility criteria:
inclusion criteria: 1. participants with grade n or m in the modified la classification system confirmed by endoscopy at initiation of the pre-observation period (visit 1). 2. participants with repeated acid reflux symptoms (heartburn or regurgitation) for 2 days or more in one week in the 3 weeks before initiation of initiation of the pre-observation period (visit 1). 3. participants with severity\* of moderate or higher for acid reflux symptoms (heartburn or regurgitation) in the 3 weeks before initiation of the pre-observation period (visit 1) \* severity: no symptoms, very mild (symptoms present but often forgotten), mild (not so painful), moderate (rather painful), severe (painful) and very severe (painful enough to affect night time sleep or daily activities) 4. outpatients (hospitalization for testing possible) exclusion criteria: 1. participants with an esophagus-related complication \[barrett's esophagus (3 cm or more, lsbe), eosinophilic esophagitis, esophageal varices, scleroderma, viral or fungal infections, esophageal stenosis, etc.\], or a history of radiotherapy or cryotherapy of the esophagus, a caustic or physiochemical trauma (esophageal sclerotherapy, etc.). however, participants with barrett's esophagus (less than 3 cm, ssbe) or schatzki's ring (mucosal tissue ring around inferior esophageal sphincter) are allowed to be included. 2. participants who have received surgery or treatment affecting gastroesophageal reflux (cardioplasty, dilation of esophageal stenosis \[excluding schatzki's ring\], etc.), or who have a history of surgery of stomach or duodenum (excluding removal of benign polyp under endoscopy) 3. participants who have acute upper gastrointestinal bleeding, gastric ulcers (mucosal defects associated with white coating) or duodenal ulcers (mucosal defect with white coating) within 30 days before initiation of the pre-observation period (visit 1) however, participants with gastric or duodenal erosions are allowed to be included. 4. participants with acute gastritis or acute exacerbation of chronic gastritis as a complication 5. participants with a previous or current history of the zollinger-ellison syndrome or other gastric acid hypersecretion disorders 6. participants with a history of chest pain due to heart disease or with chest pains suspected of being caused by heart disease within one year before initiation of the pre-observation period (visit 1)

Keywords: drug therapy
reference values of circulating endothelial progenitor cells

Conditions: Aortic Aneurysm

Summary: circulating endothelial progenitor cells cd34+144+cd14- et cd34+vegf-r2+cd14- have been shown to be inversely correlated to aortic aneurysm size. however reference values have not yet been determined. this study is aimed to determine reference values of cd34+144+cd14- et cd34+vegf-r2+cd14- in healthy men and women blood donors.

at the time of blood donation, 10ml of blood will be used to calculate the concentration of circulating endothelial progenitor cells cd34+144+cd14- et cd34+vegf-r2+cd14- , and the ratio of circulating endothelial progenitor cells cd34+144+cd14- et cd34+vegf-r2+cd14- / all circulating endothelial progenitor cells in order to determine reference values.

Eligibility criteria:
inclusion criteria: * blood donors exclusion criteria: * age over 65 * arterial hypertension (treated or not) * vascular disease * smoker or former smoker who stopped smoking for less than a year

Keywords: endothelial progenitor cells healthy blood donors
sympathetic nervous system inhibition for the treatment of diabetic kidney disease

Conditions: Diabetic Nephropathies

Summary: the purpose of this study is to determine whether moxonidine is effective in reducing urine albumin levels in patients with diabetic kidney disease.

this study will investigate the effect of moxonidine in lowering urine albumin excretion and limiting further damage to the kidneys in patients with diabetic nephropathy. reducing urine albumin excretion in type 2 diabetic patients is an indicator of successful treatment. previous studies have shown that drugs that work in a similar fashion to moxonidine (intervene with the sympathetic nervous system)have been very effective in reducing the amount of albumin in the urine and are associated with long term renal and cardiovascular protection.

Eligibility criteria:
inclusion criteria: * age: 18-75 years * diabetic nephropathy as defined by the mean of three consecutive early morning urinary albumin-creatinine ratios (uacr) of \>300mg per gram, or \> 200mg per gram in patients receiving therapy targeted at blockade of the ras exclusion criteria: * non-diabetic kidney disease * uacr of more than 3500mg per gram, an estimated glomerular filtration rate of less than 30ml/min/1.73m2. * chronic urinary tract infection. * severe hypertension * heart failure new york heart association (nyha) class ii-iv * major cardiovascular disease within the previous 6 months * left ventricular ejection fraction \<55%
pain in inflammatory joint diseases

Conditions: Arthritis; Arthritis, Juvenile Idiopathic; Arthritis,Rheumatoid; Arthritis, Reactive; Arthritis, Psoriatic; Spondyloarthritis (SpA)

Summary: our primary objective is to better understand the etiology and consequences of chronic paint by using an explorative approach to identify phenotypes and endotypes of patients with inflammatory arthritis, with a special focus on central sensitization and cognitive functioning as a key element in chronic pain. we will also examine the risk factors and clinical impact of these factors on pain, disease activity and treatment effects in a longitudinal study of patients with inflammatory joint disesases.


Eligibility criteria:
inclusion criteria: * all patients who initiate or switch biological or targeted synthetic dmards exclusion criteria: * none
study assessing metabolism, excretion and pharmacokinetics of a poly (adp-ribose) polymerase (parp) inhibitor in patients with solid metastatic tumours

Conditions: Neoplasm Metastasis

Summary: open, non-randomized, radiolabelled, single centre study designed to characterize the metabolism, excretion and pharmacokinetics of a single oral dose of 100 mg \[14c\]-radiolabelled azd2281 (ku-0059436) in patients with advanced or metastatic solid tumours.


Eligibility criteria:
inclusion criteria: * histologically confirmed advanced or metastatic tumour, refractory to standard therapies exclusion criteria: * anti-cancer therapy including chemotherapy, radiotherapy (excluding palliative radiotherapy), endocrine therapy, immunotherapy or use of other investigational agents within 4 weeks prior to study entry. * patients may continue the use of lhrh agonists for cancer, bisphosphonates for bone disease and corticosteroids provided the dose is stable before and during the study. * females will be able to continue to take hormone replacement therapy

Keywords: poly(adp ribose) polymerases metastatic solid tumours
il 6 measurement using a new densitometric bedside (poc) test

Conditions: Sepsis, Septic Shock

Summary: in a equivalence analysis, we determined whether il-6 can be assessed using a new densitometric point-of-care (poc) assay (turn-around -time: 20 minutes).il-6 measurements were compared to test results obtained with conventional elisa analysis

in an equivalence analysis, we determined whether il-6 can be assessed using a new densitometric point-of-care (poc) assay (turn-around -time: 20 minutes) that allows il-6 measurements at the bedside. we then compared the respective test results to those obtained with conventional elisa analysis

Eligibility criteria:
inclusion criteria: * age 18-90 * written informed consent
observational study of infants born at 34 to 37 weeks of gestation until the age of 1 year

Conditions: Respiratory Distress; Hypoglycemia; Feeding Intolerance; Jaundice; Hypothermia; Developmental Delay

Summary: late preterm infants are at an increased risk for short and long term morbidity (during the 1st year of life, their neurodevelopmental status may also be delayed as compared to infants born at term). the term "near term infants" is probably a deceiving one.

the study will include all near term infants born at 3 israeli medical centers during a one year period.

Eligibility criteria:
inclusion criteria: * gestational age 34wks- 37wks * singleton * without chromosomal abnormalities or malformations exclusion criteria: * no chromosomal abnormalities * malformations

Keywords: late preterm infants near term infants outcome
a predictive tool for predicting adverse outcomes in acute pulmonary embolism patients using ctpa.

Conditions: Pulmonary Embolism and Thrombosis; Deterioration, Clinical

Summary: this study collected clinical, laboratory, and ct parameters of acute patients with acute pulmonary embolism from admission to predict adverse outcomes within 30 days after admission into hospital.

this study collected clinical, laboratory, and ct parameters of acute patients with acute pulmonary embolism from admission. the outcomes of interest were defined as the occurrence of adverse outcomes within 30 days after admission into hospital. eligible patients were randomized in some ratio into derivation and validation cohorts. the derivation cohort was used to develop and evaluate a multivariable logistic regression model for predicting the outcomes of interest. the discriminatory power was evaluated by comparing the nomogram to the established risk stratification systems. the consistency of the nomogram was evaluated using the validation cohort.

Eligibility criteria:
inclusion criteria: * age of ≥ 18 years and a pe diagnosis based on ct pulmonary angiography exclusion criteria: * pregnancy * reception of reperfusion treatment before admission * missing data regarding ct parameters, echocardiography, cardiac troponin i (c-tn i), and n-terminal-pro brain natriuretic peptide (nt-pro bnp) levels.

Keywords: pulmonary embolism and thrombosis deterioration, clinical
predictors of range of motion and balance abnormalities in children diagnosed with cerebral palsy

Conditions: Cerebral Palsy

Summary: 1. to better understand the factors that contribute to rom abnormalities in children diagnosed with cp. 2. to describe the distribution of primary (muscle tone and postural stability)and secondary impairments (rom and functional muscle strength) across the gross motor spectrum measured by gmfcs scores. 3. to evaluate the effects of primary and secondary impairments on gross functional outcome in children with spastic cp. 4. to find any possible correlation between clinical variables.


Eligibility criteria:
inclusion criteria: * only children with clinical diagnosis of cerebral palsy , who were receiving physiotherapy services at the paediatric out-patient clinic of faculty of physical therapy, cairo university for a minimum of six months regularly. exclusion criteria: * children were excluded if they had one or more of the following: behavioral issues, a history of persistent heart or chest disease, significant visual or auditory impairment, botulinum toxin injection at last six months prior to the study.
dietary sodium intake in acute heart failure

Conditions: Heart Failure; With Decompensation; Heart Failure，Congestive

Summary: this study is design to assess two levels of dietary sodium intake in the treatment of patients with acute decompensated heart failure.

this study aim at assessing the effect of two levels of dietary sodium intake during seven days in hospitalized patients with acute decompensated heart failure. it is a prospective cohort, randomized, with blinded intervention groups: low sodium diet (the patients will receive 3 g/day of dietary sodium intake), and normal sodium diet (patients will receive 7 g/day of dietary sodium intake). besides that, both groups will be submitted to a fluid intake limited to 1000 ml/day.

Eligibility criteria:
inclusion criteria: * patients with acute decompensated heart failure diagnosis, filling the framingham diagnostic criteria, hospitalized at campus hospital das clínicas of ribeirão preto. exclusion criteria: * creatinine clearance \<30 ml / min / 1.73 m²; * acute coronary syndrome; * stroke; * dementia; * severe cognitive impairment; * cancer; * decompensated diabetes mellitus; * severe liver disease; * septic shock or with clinical signs of sepsis; * chronic renal parenchymal disease prior to the start of the study; * adhf secondary to acute renal failure; * nutritional disorders or those who are unable to take oral intake because of vomiting, dysphagia or gastroenteritis.

Keywords: hyponatremia sodium intake blood pressure sodium chloride
the contribution of heels for walking quality among children with muscular dystrophy

Conditions: Step Time and Length; Symmetry; Step Time and Length Variability; Heart Rate; Gait Velocity

Summary: during the stand phase the dmd foot is too plantarflexed in addition patients adopt a higher flexion and abduction of the hip in order to advance the swinging limb. the aim of this work is to assess the immediate contribution of heels for these walking disturbance in children with muscular dystrophy disease.


Eligibility criteria:
inclusion criteria: * age \>6 yrs * walk without heel strike exclusion criteria: * cannot understand simple instructions